Update from the ongoing phase 1/2 registrational trial of repotrectinib: Results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) Meeting Abstract
| Authors: | Besse, B.; Springfeld, C.; Baik, C.; Hervieu, A.; Solomon, B.; Moreno, V.; Bazhenova, L.; Goto, K.; Kim, Y. C.; Lu, S.; Sun, M.; Trone, D.; Thamake, S.; Cho, B. C.; de Langen, A.; Popat, S.; Wolf, J.; Moro-Sibilot, D.; Fang, J.; Drilon, A. |
| Abstract Title: | Update from the ongoing phase 1/2 registrational trial of repotrectinib: Results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1) |
| Meeting Title: | 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics |
| Journal Title: | European Journal of Cancer |
| Volume: | 174 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2022 Oct 26-28 |
| Meeting Location: | Barcelona, Spain |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2022-10-01 |
| Start Page: | S75 |
| End Page: | S76 |
| Language: | English |
| DOI: | 10.1016/s0959-8049(22)01000-0 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| DOI/URL: | |
| Notes: | Meeting abstract: 209 (PB089) -- In Poster Session -- Source: Cinahl |
